For patients with Stages III and IV disease, surgery is usually followed with an additional adjuvant therapy. Ask your physician to explain the possibilities and grounds for selection of one treatment over the other.
Select a treatment to learn more about it.
A number of drugs active in fighting cancer cells are being used to treat melanoma, either one at a time or in combinations. Currently, Dacarbazine (DTIC), given by injection, is the only chemotherapy approved by the Food and Drug Administration (FDA). DTIC may be combined with carmustin (BCNU) and tamoxifen, or with cisplatin and vinblastine. Temozolomide, an oral drug closely resembling DTIC, is FDA-approved for brain cancers but also used off-label for melanomas that have spread to the brain or nervous system. Similarly, a drug called Abraxane, already approved for breast cancer, non-small cell lung cancer, and late-stage pancreatic cancer, produced striking results in a Phase III study of 529 late-stage melanoma patients, halting the disease’s advance for 4.8 months, almost twice as long as standard DTIC treatment. Median survival was also almost two months longer than with DTIC. Abraxane could soon be submitted to the FDA for approval, and would be the first melanoma chemotherapy approved in 38 years.
Another class of drugs, based on a different principle, has come into use more recently. They are anti-angiogenic, which means that they prevent new blood vessels from forming. The reason this is important is that they cut off the blood supply that would otherwise nourish the cancer cells and enable them to grow. These drugs are still experimental for melanoma, and a good deal of research into improving and combining them with others is going on. Studies are under way with the anti-angiogenic drug thalidomide, combined with the chemotherapeutic agent, temozolomide. Angiostatin and endostatin are two other drugs in this class that have shown some degree of activity against melanoma in preliminary studies.
Isolated Limb Perfusion Method: This palliative treatment, which relieves symptoms, is sometimes used when melanoma metastases have reached an arm or leg. “Isolated” means that the chemotherapy is “perfused” (shunted directly) to the blood flowing through the affected limb, but to no other part of the body, to limit toxic effects. The drug melphalan is the chemotherapy most frequently used, often combined with other agents.
This is one of the most exciting and changing fields in medicine, based on drugs that act on the body's immune system. A number of newly developed treatments are now being tested with some success. Among the immunotherapies, several types of experimental melanoma vaccines are now viewed as promising. Unlike the influenza vaccine, given when you are well to prevent disease, these are given to people who already have melanoma. Clinical trials of various types of vaccine are under way with patients whose disease is in Stages III and IV. The vaccines are intended to stimulate the immune system so that it reacts more strongly against a patient's melanoma cells, destroying the cancer or slowing the progression. These vaccines are not a part of routine treatment at this time, so patients with advanced melanomas may wish to discuss this possibility with their physicians.
Another type of immunotherapy (also known as biologic therapy) makes use of chemicals that occur naturally in the body. One therapy you are likely to hear about is injectable interferon (IFN) alpha-2b, the only drug with FDA approval to treat “high-risk” Stage II and Stage III melanomas. High-risk melanomas are tumors that have a high chance of recurring (such as those that are ulcerated or over 4 mm thick) or have spread to the nearby lymph nodes. At first, IFN alpha-2b appeared to increase overall 5-year survival. After further study, it proved to give patients a longer period without relapse, extending their disease-free interval to an average of 9 months, but did not lengthen overall survival. It has significant flu-like side effects.
In 2011, the FDA approved a new drug, peginterferon alfa-2b (also known as Sylatron), to treat Stage III melanoma patients – those found to have microscopic or palpable metastatic disease that has reached the lymph nodes. The drug, injected subcutaneously, was the first adjuvant, or additional, therapy for Stage III patients approved since high-dose IFN alfa-2b in 1995. This approval followed on the heels of a trial in which melanoma patients taking Sylatron remained relapse-free an average of nine months longer than patients not taking the drug (34.8 months vs. 25.5 months). There was no difference in overall survival.
Tumor necrosis factor (tumor-killing) factor is another of these naturally occurring substances. Both of these — especially interferon alpha-2b — are produced by white cells (lymphocytes) when they come in contact with tumor cells, viruses or other harmful substances, and have been shown to kill a number of tumors, including melanomas. They have some anti-angiogenic properties as well. However, both drugs have significant side effects that can limit their use. And while interferon alpha-2b is FDA-approved, tumor necrosis factor is not.
Lymphokines, immune chemicals naturally produced by the white blood cells in small quantities, are being used for Stage IV patients. They may also be produced by white blood cells that have been specially stimulated by antigens, a basic part of the immune system, to make them better “killers” of malignant cells. The best known of these therapies uses the injectable lymphokine interleukin-2 (IL-2), with or without the addition of interferon alpha or other biotherapies and chemotherapies. It enters melanoma cells and attacks them. High-dose IL-2 (“Proleukin”) was the first FDA-approved immunotherapy used to treat Stage IV metastatic melanoma. It is associated with very significant side effects when given in high doses, but has been found to increase disease-free and overall survival in some patients. About 10-16 percent of carefully selected patients on IL-2 regimens respond to the drug, with 6 percent having complete responses (remissions), and about 60 percent of the complete responders have significantly extended lives.
Tumor-infiltrating lymphocytes (TILs) also play a part in some new therapies for advanced melanoma. Of special note is a technique from the National Cancer Institute called adoptive cell transfer (ACT), which involves harvesting TILs from the patient’s blood, then isolating from them the cells expressing T cell receptors that can recognize melanoma-specific antigens; in other words, the most aggressive melanoma-killing lymphocytes are identified and isolated. These are then grown in large numbers in the lab and reinjected into the patient in the hope that they will massively attack the patient’s melanoma cells. High doses of IL-2 may be added to make these tumor-fighting cells mature and multiply, and certain drugs are used to eliminate immune factors that might inhibit the tumor-fighting cells; this is called lymphodepletion. In clinical trials with metastatic melanoma patients who had not responded to previous treatment, the patients’ response rates have been far higher than those seen with chemotherapy.
In the latest trials, total-body irradiation was added to enhance lymphodepletion, and response rates up to 72 percent were observed in 93 patients, with 11 achieving complete remissions lasting 18 to 75 months or more.
Checkpoint Blockade Therapy
Anti-CTLA-4 therapy is another important new direction for melanoma immunotherapy. CTLA-4 is a kind of natural “brake” in the immune system that can inhibit activation of healing T-cells to keep them from overproducing. Anti-CTLA-4 therapies are designed to block CTLA-4 so that more T-cells can be produced when needed to fight a cancer. In fact, the therapy is also referred to as “checkpoint blockade” immunotherapy.
The first successful checkpoint blockade therapy was ipilimumab (YervoyTM), approved by the FDA in 2011 for patients with advanced melanoma. A monoclonal antibody (a purified class of antibodies cloned and mass-produced in the lab from one specific type of cell or cell line) that blocks CTLA-4, ipilimumab has yielded dramatic, sustained responses akin to “cures” in certain patients, with some surviving more than 5 years. In a study of 676 people with advanced, inoperable melanoma (reported in June, 2010 at the American Society for Clinical Oncology annual meeting), 24 percent of patients given ipilimumab alone or combined with another immune-stimulating treatment were alive after two years, vs. only 14 percent of those given the other immune-stimulating treatment alone. In a later study of 1,861 patients treated with ipilimumab, about 22 percent lived three years or longer, and 84 percent of those survivors were estimated to be alive after 5 years and 10 years.
Two additional immune-checkpoint-blockading drugs, nivolumab and MK-3475 (pembrolizumab), are in late-stage clinical trials and are likely to be FDA-approved in 2014 or 2015. Both inhibit another molecule (programmed death-1, or PD-1) that suppresses T-cells. PD-1 can directly interact with tumor cells by binding to a molecule called programmed death ligand-1 (PD-L1), and cancer cells may use PD-L1 to hide from attack by T-cells, but these drugs can release the T-cells to fight the cancer. A third drug, MPDL3280A, is designed to inhibit PD-L1, and appears to hold promise in early clinical studies. Initial results indicate that PD-1/PD-L1 blockade results in higher response rates and a more favorable side effect profile than that seen with ipilmumab. Several randomized trials comparing ipilimumab with anti-PD-1 therapy are ongoing.
Targeted therapies are types of treatment that use drugs or other substances to identify and attack specific types of cancer cells, or to block the action of certain enzymes, proteins or other molecules that promote the growth and spread of cancer cells.
In the past few years, there have been several notable successes in targeted melanoma therapy. The first was vemurafenib (Zelboraf TM), FDA-approved in 2011, which inhibits the gene called BRAF. BRAF produces a protein that normally regulates skin cells, causing them to multiply only when growth is needed. However, a specific mutated version of BRAF called v600E (found in about half of all melanoma patients) produces an abnormal version of the protein that stays switched on. This leads to out-of-control growth, i.e., cancer. Vemurafenib can bind to the defective protein and deactivate it. Phase I and II studies showed striking and rapid antitumor activity in patients with BRAF v600E-mutated melanoma. Then, a randomized Phase III trial comparing vemurafenib to standard chemotherapy showed both a progression-free and overall survival (OS) advantage in vemurafenib patients (median OS of 13.6 months for vemurafenib patients vs. 9.7 months for chemotherapy patients). As with imatinib, the hope is that altering the dosing regimen and combining vemurafenib v with other therapies will significantly lengthen survival. In 2013, two other treatments directed toward BRAF and a related molecule called MEK were also approved: the BRAF inhibitor dabrafenib (Taflinar®) and the MEK inhibitor trametinib (Mekinist®). Recently, the FDA also approved the use of these two drugs in combination for patients with inoperable or metastatic melanoma with a BRAF V600E or V600K mutation. The hope is that these different drugs and drug combinations will increase tumor shrinkage and extend the length of time before the melanoma starts growing again.
Another targeted therapy, imatinib (Gleevec), has produced encouraging but mixed early results in metastatic melanoma, and greater numbers of patients must be tested. Imatinib inhibits c-KIT, the receptor for an enzyme called tyrosine kinase, which has been associated with some cancers, including melanoma. Genetic aberrations or mutations in KIT have been frequently found in certain gastrointestinal tumors and leukemias, which have responded well to treatment with imatinib. Some types of melanoma also frequently have KIT mutations, so it has been hypothesized that these melanomas will similarly respond to imatinib treatment. Indeed, lab experiments have been promising, and some patients, especially those with acral lentiginous melanoma and mucosal melanoma, have initially responded well, but thus far, significant clinical improvements from the drug as a single therapy have been minimal. Imatinib is continuing to be tested in different dosage regimens and combined with other therapies.
BRAF and MEK Inhibitors vs. Immune-Checkpoint Blockade Therapies
Although the likelihood of a melanoma shrinking when treated with BRAF and MEK inhibitors is high, the response to this targeted treatment often lasts for a limited period. Ipilimumab is less likely to shrink metastases, and it usually takes weeks to months before improvements are seen. However, in patients who respond, ipilimumab offers greater potential for long-term control of the melanoma and more prolonged survival. The new experimental immune-checkpoint blockade therapies – nivolumab and MK-3475 – appear to offer even longer-lasting effects comparable to ipilimumab, and may bring about a more rapid response, shrinking the melanoma.
Combining Targeted Therapy and Immunotherapy
Both targeted drugs and immunotherapy are now important treatment options, though the best ways to use them are not yet clear. Because of the substantial melanoma-killing activity of BRAF and MEK inhibitors, it may be particularly attractive to combine them with ipilimumab or other checkpoint-blockade immunotherapies. It is hypothesized that by killing melanoma cells, BRAF and MEK inhibitors will increase activation of immune cells to attack any remaining melanoma cells. However, initial attempts to combine a BRAF inhibitor (vemurafenib) with immune-checkpoint blockade therapy (ipilimumab) was deemed unsafe, so this combination should not currently be used in standard practice. Clinical trials are now evaluating combinations of these drugs used in different ways -- for example, using them in sequence rather than concurrently.
Next Steps: Improving Long-term Survival
The advances in understanding melanoma and the immune system have set the stage for continual improvements in the treatment of advanced disease. Some patients have already derived significant long-term benefits. One recent report suggested that 20 percent of patients who received ipilimumab are alive after 10 years. (In contrast, only about 4-6 percent of patients were ever found to achieve long-term survival with Interleukin-2, and no overall survival advantage was ever demonstrated with chemotherapy.) Similarly, early clinical trials have described an improved likelihood of significant tumor shrinkage using combinations of these new drugs, specifically dabrafenib combined with trametinib or ipilimumab with nivolumab.
The next goal will be to determine which combinations and methods are most suitable to shrink melanoma most effectively, maintain the best possible quality of life for patients and extend patients’ lives as long as possible. Many other novel approaches are also on the horizon, currently either in active laboratory study or clinical trials; the hope is to turn metastatic melanoma from a deadly disease into a manageable chronic condition.
A gene is the basic unit of genetic material. It is the code or "blueprint" by which our body's proteins are made. Alterations in these codes can result in uncontrolled cell growth as in cancer.
On the other hand, selected genes can be altered so as to correct genetic defects or enhance the cancer-fighting potential of cells. There is hope that making changes in genes will lead to successes in treating a wide range of illnesses, so this kind of therapy frequently gets newspaper headlines. However, keep in mind that this treatment is in the very early stages of research, and its effectiveness is yet to be proven conclusively.
One form of gene therapy is based on creating alterations in the white blood cells or in the tumor-infiltrating lymphocytes (TILS) so that they will attack the melanoma. This is achieved by removing these cells from the patient, growing them outside the body and treating them so as to increase their number. The next step is the addition of genetic material that produces one of the many growth factors which make the lymphocytes more aggressive as cancer-fighters. These more aggressive lymphocytes are returned to the patient's body in an effort to stimulate the immune system to kill the melanoma and its metastases.
The focus of current research is the identification of genes for specific melanoma antigens. These are molecules found on the cell wall that stimulate the production of antibodies, which are a part of the body's immune defense system. An antibody attaches itself to only one type of antigen. By injecting the gene for the melanoma antigens, the hope is to increase their number and produce a broad attack by the patient's immune system.
Many patients, especially those with advanced disease, are participating in clinical trials to obtain new treatments that are still experimental and not generally available.
Patients who have Stage III and IV melanoma might consider enrolling in a clinical trial of a new or experimental treatment. There are risks involved in enrolling in a clinical trial, but there can be benefits as well. More treatment possibilities exist than ever before, giving new hope to people with melanoma.